GSK set to use uHTS screen from Evotec
Glaxo SmithKline has installed an Evoscreen Mark II automated miniaturised system for ultra-high throughput screening from Evotec Biosystems at its research site in Harlow, UK.
The system, which has been designed specifically for GSK, has been undergoing testing by GSK scientists in Hamburg, Germany. These tests proved the system's robustness, and three biological assays were successfully performed in ultra-high throughput format using different read-out parameters.
The system is accurate to 1µl, and Evotec is now working on the next generation of the technology, which integrates further technological advances, notably in the field of cellular assays.